SuperGen up on Phase I/II decitabine data

SUPG was up $4.063 (31 percent) to $17 on Thursday after publishing in Blood data from an 8-patient U.S. Phase I/II trial showing that its decitabine chemotherapeutic modulator of DNA methylation was...